We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+29.17%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$836M
AUM Growth
+$210M
Cap. Flow
+$82.3M
Cap. Flow %
9.85%
Top 10 Hldgs %
42.54%
Holding
96
New
9
Increased
7
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$15.2M
2
CLLS
Cellectis
CLLS
+$13.9M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.6M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.74M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.21M

Top Sells

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$7.23M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$5.84M
3
ARRY
Array Biopharma Inc
ARRY
+$3.88M
4
CRIS icon
Curis
CRIS
+$3.59M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$3.17M

Sector Composition

Rank Sector Weight
1 Healthcare 91.58%
2 Miscellaneous 8.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
26
Collegium Pharmaceutical
COLL
$739M
$12.4M 1.48%
450,000
– –
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$1.28B
$12.3M 1.47%
109,500
– –
RMTI icon
28
Rockwell Medical
RMTI
$31.6M
$11.3M 1.35%
10,045
– –
VTAE
29
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$11.3M 1.35%
+623,409
New +$8.58M
BCRX icon
30
BioCryst Pharmaceuticals
BCRX
$2.14B
$11.1M 1.33%
1,080,000
– –
MYOK
31
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11M 1.32%
+753,388
New +$9.21M
XLRN
32
DELISTED
Acceleron Pharma
XLRN
$9.75M 1.17%
200,000
– –
MCRB icon
33
Seres Therapeutics
MCRB
$44.2M
$8.77M 1.05%
12,500
– –
LPCN icon
34
Lipocine
LPCN
$18.2M
$8.62M 1.03%
39,216
– –
ADXS
35
DELISTED
Advaxis Inc
ADXS
$8.05M 0.96%
53,333
– –
CTMX icon
36
CytomX Therapeutics
CTMX
$604M
$7.74M 0.93%
+371,023
New +$5.87M
PFNX
37
DELISTED
Pfenex Inc.
PFNX
$7.74M 0.93%
624,900
– –
AGEN
38
Agenus
AGEN
$326M
$7.08M 0.85%
79,431
– –
SCTL
39
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$7.02M 0.84%
869,700
– –
NERV icon
40
Minerva Neurosciences
NERV
$171M
$6.95M 0.83%
143,130
– –
FWP
41
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$6.37M 0.76%
47,867
– –
WVE icon
42
Wave Life Sciences
WVE
$881M
$6.25M 0.75%
+392,079
New +$6.15M
BLCM
43
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$6.08M 0.73%
+30,000
New +$5.37M
DERM
44
DELISTED
Dermira, Inc.
DERM
$5.88M 0.7%
170,000
– –
ACHN
45
DELISTED
Achillion Pharmaceuticals
ACHN
$5.39M 0.65%
+500,000
New +$4.55M
INDP icon
46
Indaptus Therapeutics
INDP
$418M
$4.29M 0.51%
357
– –
EPZM
47
DELISTED
Epizyme, Inc
EPZM
$4.26M 0.51%
266,250
– –
KITE
48
DELISTED
Kite Pharma, Inc.
KITE
$4.24M 0.51%
68,800
– –
CYAD
49
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$4.09M 0.49%
75,000
– –
ATRA icon
50
Atara Biotherapeutics
ATRA
$99.1M
$3.96M 0.47%
6,000
– –
1
2
3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Cormorant Asset Management held 96 positions worth $836M, up 34% from $626M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Cormorant Asset Management deployed $82.3M of net new capital in Q4 2015, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was MacroGenics: 500,000 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regulus Therapeutics, an estimated $7.23M trimmed.

  • Cormorant Asset Management's largest Q4 2015 buy was MacroGenics: 500,000 shares worth $15.5M.
  • Cormorant Asset Management added most to Cellectis in Q4 2015, an estimated $13.9M increase.
  • Cormorant Asset Management's biggest Q4 2015 reduction was Regulus Therapeutics, cutting an estimated $7.23M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q4 2015, selling an estimated $3.88M.
  • Cormorant Asset Management's ten largest holdings make up 43% of its $836M portfolio in Q4 2015.
  • Cormorant Asset Management opened 9 new positions and closed 14 in Q4 2015.
  • Cormorant Asset Management's portfolio value rose 34% quarter-over-quarter to $836M.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.